The new 2023 endometrial cancer FIGO staging system: balancing innovation with complexity
- 11 April 2025
- journal article
- review article
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 35 (8) , 101823
Abstract
No abstract availableKeywords
This publication has 52 references indexed in Scilit:
- Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin–paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trialAnnals of Oncology, 2024
- FIGO staging of endometrial cancer: 2023International Journal of Gynecology & Obstetrics, 2023
- Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- Substantial lymphovascular space invasion predicts worse outcomes in early-stage endometrioid endometrial cancerBrachytherapy, 2021
- Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta‐analysisCancer, 2021
- Semiquantitative evaluation of lymph-vascular space invasion in patients affected by endometrial cancer: Prognostic and clinical implicationsEuropean Journal of Cancer, 2021
- Interpretation of somatic POLE mutations in endometrial carcinomaThe Journal of Pathology, 2019
- The genetic landscape of endometrial clear cell carcinomasThe Journal of Pathology, 2017
- Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer – A pooled analysis of PORTEC 1 and 2 trialsEuropean Journal of Cancer, 2015
- Surgical Staging of Endometrial Cancer: Evolution, Evaluation, and Responsible Challenge—A Personal PerspectiveGynecologic Oncology, 1997